At a glance

What is selank?

Selank, sometimes shorthanded as TP-7, is a synthetic seven-amino acid peptide, a stabilized analog of a natural peptide called tuftsin. It was developed by Russian research institutes and is approved in Russia as an anti-anxiety agent. Outside Russia it is sold through wellness and "research peptide" channels for anxiety and focus, and it is not an approved medicine in the United States.

How does it work?

Selank is proposed to have calming effects by modulating the brain's enkephalin and GABA systems, influencing serotonin metabolism, and affecting levels of a nerve-growth signal called BDNF. These mechanisms come mainly from animal and laboratory work. This describes the proposed mechanism, separate from demonstrated benefit in people.

Is it FDA-approved?

No. Selank is not approved by the FDA. It is approved as an anxiolytic in Russia. In the United States it is sold only as a "research chemical," is not on FDA compounding lists, and was not among the peptides reviewed favorably at the 2026 FDA compounding advisory meetings.

What does the research show?

There is some human evidence, but of limited quality. Small Russian studies have reported anxiety-reducing effects, including a comparison with a benzodiazepine and a study¹ suggesting selank reduced benzodiazepine side effects. These trials are generally:

• Small
• Single-country
• Often conducted by the developing institutions
• Published in Russian
• Not independently replicated

An analytical review² notes that such peptides have not completed clinical trials to Western regulatory standards. The evidence does not establish efficacy by those standards.

What is the difference between selank and semax?

Selank and semax are both synthetic seven-amino acid peptides developed by Russian research institutes, and the main difference is the natural molecule each is based on and the use each is approved for in Russia. Their proposed mechanisms are also described differently.

Both mechanism descriptions come mainly from animal and laboratory work, and neither has been shown to produce a benefit in people. The advisory vote is the one U.S. regulatory difference, and an advisory vote is only a recommendation; it does not make semax approved.

The human evidence for both is limited in the same way: small, mostly Russian studies, often run by the developing institutions and not independently replicated. An analytical review² notes that such peptides have not completed clinical trials to Western regulatory standards. The evidence does not establish that either one works or that one works better than the other.

Frequently asked questions

Is selank FDA-approved?

No. Selank is not FDA-approved for any indication in the United States. It is approved in Russia as an anti-anxiety medicine, where trials studied it in people with generalized anxiety disorder and neurasthenia⁵. As of September 2026, FDA lists selank acetate as nominated but withdrawn⁶, and it is not on the 503A bulks list, so compounding pharmacies in the US cannot use it as an ingredient.

Is selank legal to buy in the US in 2026?

As of September 2026, selank is not eligible for compounding under Section 503A. Selank products sold online without a prescription are not FDA-regulated; they have received no quality, purity, or concentration oversight. Obtaining selank from an online vendor carries both regulatory and product-quality risks.

What is the difference between selank and semax?

Selank derives structurally from tuftsin and is studied primarily as an anxiolytic with secondary immunomodulatory properties⁷. Semax derives structurally from ACTH 4-7³ and is studied primarily as a neuroprotective and nootropic compound with proposed BDNF-upregulating effects. Both were developed by Russian research institutes and use intranasal delivery, but they have different proposed mechanisms, different primary studied effects, and different approved indications in Russia. They are not interchangeable.

What does the published research on selank show?

Russian clinical data report anxiety-reducing effects similar to the benzodiazepine medazepam⁵, and adding selank to phenazepam reduced that drug's side effects, including sedation¹; quantitative effect sizes versus benzodiazepine comparators were not reported in the English-language abstracts. One proposed mechanism, from rat gene-expression work, is allosteric modulation of the GABA system⁸. No Western RCTs have replicated these findings.

What is the primary route of administration in selank research?

Intranasal delivery is the primary route studied in selank research. A 2016 mouse study found that intranasal and intraperitoneal selank both reduced anxiety-like behavior⁹ in the more anxious mouse strain, but changed different brain receptors: injection raised GABA-receptor binding in the frontal cortex, while intranasal delivery raised NMDA-receptor binding. How the route-dependent effects translate to human use is incompletely characterized.

What is the FDA Category 2 peptide list?

FDA Category 2 lists bulk drug substances that raise significant safety risks under Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding. As of September 2026, Category 2¹⁰ holds only cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine for intrauterine use. FDA removed a batch of peptides from Category 2 in April 2026 after their nominators withdrew the nominations. Selank acetate left Category 2 before that batch, also after a withdrawn nomination, and sits in the nominated-but-withdrawn table⁶.

Are peptides legal again after the April 2026 Category 2 removals?

No. FDA's April 2026 removal of peptides from Category 2 followed withdrawn nominations and did not make them eligible for compounding. A withdrawn substance is not on the 503A bulks list or in Category 1 unless FDA later adds it. Selank is not eligible for 503A compounding as of September 2026. Whether a specific peptide can be compounded depends on its individual status, not a blanket rule about peptides generally.

Will selank become available through compounding pharmacies again?

This depends on whether FDA adds selank to the 503A bulks list or places it in Category 1. As of September 2026, selank is not on the July 2026 advisory committee agenda¹¹, and no public timeline for a determination has been announced. Monitoring FDA's bulk drug substance rulemaking updates is the most reliable way to track this.

More for brain & sleep